MARC Record from harvard_bibliographic_metadata

LEADER: 07202cam a22004334a 4500
001 011491646-2
005 20080718123330.0
008 080212s2008 nyua b 001 0 eng
010 $a 2008006861
020 $a9780387788173
035 0 $aocn192042330
040 $aDNLM/DLC$cDLC$dDLC
042 $apcc
050 00 $aRC268.2$b.I56 2008
060 10 $aW1$bAD559 v.630 2008
060 10 $aWP 870$bI565 2008
082 00 $a616.99/4071$222
245 00 $aInnovative endocrinology of cancer /$cedited by Lev M. Berstein, Richard J. Santen.
260 $aNew York :$bSpringer Science+Business Media ;$aAustin, Tex. :$bLandes Bioscience,$cc2008.
300 $axix, 242 p. :$bill. ;$c26 cm.
440 0 $aAdvances in experimental medicine and biology ;$vv. 630
504 $aIncludes bibliographical references and index.
505 0 $a1. Mechanisms of Hormone Carcinogenesis: Evolution of Views, Role of Mitochondria / Jin-Qiang Chen, Terry R. Brown and James D. Yager -- A Novel Paradigm: Estrogen/Estrogen Receptor-Mediated Mitochondrial Pathway -- Potential Role of E₂/ER-Mediated Mitochondrial Pathway in Estrogen Carcinogenesis -- Deregulation of Mitochondrial Bioenergetics in Cancer Cells and Involvement of Estrogens and ERs -- Concluding Remarks, Evolutionary View and Future Directions -- 2. Adaptation to Estradiol Deprivation Causes Up-Regulation of Growth Factor Pathways And Hypersensitivity to Estradiol in Breast Cancer Cells / Richard J. Santen, Robert X. Song, Shigeru Masamura, Wei Yue, Ping Fan, Tetsuya Sogon, Shin-ichi Hayashi, Kei Nakachi and Hidtek Eguchi -- Phenomenon of Hypersensitivity: Mechanisms and Pathways -- Significance of Our Findings to Development of Further Therapies -- Synthesis of Our Current Thinking.
505 0 $a3. Role of Endocrine-Genotoxic Switchings In Cancer and Other Human Diseases: Basic Triad / Lev M. Berstein -- General Principle: Types of Effects -- Phenomenon of Switching of Estrogen Effects (PSEE) -- Janus (Dual) Function of Glucose -- Adipogenotoxicosis -- Basic Triad: Interactions and implications -- 4. Breast Development, Hormones and Cancer / Jose Russo and Irma H. Russo -- Defining the Cell of Origin of Breast Cancer -- Breast Architecture and Cancer -- 5. Epidemiology of Hormone-Associated Cancers As a Reflection of Age / Svetlana V. Ukraintseva, Konstantin G. Arbeev and Anatoli I. Yashin -- Data Sources and Basic Definitions -- Typical Age Patterns of Cancer Incidence and Mortality Rates -- Patterns and Trends of Incidence Rates for Hormone Associated Cancers -- Conclusions -- 6. Obesity and Diabetes Epidemics: Cancer Repercussions / Anette Hjartåker, Hilde Langseth and Elisabete Weiderpass.
505 0 $aCurrent Research on the Associations between Obesity and Diabetes and the Risk of Cancer -- Cancer of the Digestive Organs -- Respiratory Organs -- Skin Melanoma -- Breast Cancer -- Female Genital Organs -- Male Genital Organs -- Urinary Organs -- Thyroid Cancer -- Lymphoid and Haematopoietic Cancers -- Summary of Findings -- Concluding Remarks and Recommendations for Further Research -- 7. Progesterone Receptor Action: Translating Studies in Breast Cancer Models to Clinical Insights / Carol A. Lange, Carol A. Sartorius, Hany Abdel-Hafiz, Monique A. Spillman, Kathryn B. Horwitz and Britta M. Jacobsen -- Classical Actions of PRs -- Direct PR Phosphorylation in Breast Cancer Models -- PR Ser294 Phosphorylation in Breast Cancer Models -- Extranuclear Actions of PR -- Integration of Rapid Signaling and Nuclear SR Actions -- PR Action and Breast Cancer Cell Growth, Apoptosis and Aggressiveness in Vitro.
505 0 $aExpression Profiling in Vitro -- Progestins and Antiprogestins in Breast Tumor Models -- Progesterone Regulation of BRCA1 -- General Steroid Receptors and Breast Cancer -- Progesterone Receptors and Tamoxifen Responsiveness -- Clinical Significance of PR-A vs. PR-B: Two Subsets of ER+, PR+ Tumors? -- Concluding Remarks -- 8. Aromatase Expression in Women's Cancers / Serdar E. Bulun and Evan R. Simpson -- Pathological Expression of Aromatase in Women's Cancers -- Conclusion -- 9. Proteomics of Cancer of Hormone-Dependent Tissues / Darren R. Tyson and David K. Ornstein -- Biomarkers versus Biology -- Cancer Proteomics: Sample Sources and Methodological Approaches -- Recent Innovations and Technological Advances -- The Future of Clinical Proteomics -- 10. Endogenous Hormone Levels and Risk of Breast, Endometrial and Ovarian Cancers: Prospective Studies / A. Heather Eliassen and Susan E. Hankinson.
505 0 $aMethodologic Considerations -- Breast Cancer -- Endometrial Cancer -- Ovarian Cancer -- Conclusions -- Summary -- 11. Hormonal Heterogeneity of Endometrial Cancer / Carsten Gründker, Andreas R. Giinthert and Günter Emons -- Etiology -- Estrogen-Associated Endometrial Cancer (Type I) -- Non-Estrogen-Associated Endometrial Cancer (Type II) -- Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumors) -- Molecular Pathogenesis of Endometrial Cancer -- Hormone Receptors and Aromatase -- Future Perspective -- 12. Cell Cycle Machinery: Links with Genesis And Treatment of Breast Cancer / Alison J. Butt, C. Elizabeth Caldon, Catriona M. McNeil, Alexander Swarbrick, Elizabeth A. Musgrove and Robert L. Sutherland -- Cell Cycle Control Mechanisms and Their Regulation in Breast Cancer Cells -- Cell Cycle Control Genes as Putative Breast Cancer Oncogenes/Tumor Suppressor Genes.
505 0 $aRelationship of Cell Cycle Deregulation to Patient Outcome and Response to Endocrine Therapy -- Conclusion -- 13. Selective Estrogen Modulators As an Anticancer Tool: Mechanisms of Efficiency And Resistance / Surojeet Sengupta and V. Craig Jordan -- Estrogen, Tamoxifen and Cancer -- Molecular Mechanism of SERM Action -- Evolution of SERM Resistant Breast Cancers -- Mechanism of SERM Resistance -- Therapeutic Options for SERM Resistant Breast Cancers -- Resistance to Long Term Antihormone Therapy -- Estrogen Induced Apoptosis -- Conclusion -- 14. Pharmacogenomics of Endocrine Therapy In Breast Cancer / Richard Weinshilboum -- Tamoxifen Pharmacogenomics -- Aromatase Inhibitor Pharmacogenomics -- Conclusions and Future Directions -- 15. Prevention of Breast Cancer Using SERMs / Trevor J. Powles -- Tamoxifen Trials -- Raloxifene Trials -- Summary of SERM Breast Cancer Risk Reduction Trials -- Conclusion -- General Conclusion.
520 $aThis volume is devoted to the new developments in such topics as mechanisms of hormonal carcinogenesis, epidemiology and risk factors, hormone production by tumor tissue and hormonal sensitivity of the latter, genesis, dichotomy and endocrinology of cancer in females, pharmacogenomics and proteomics in oncoendocrinology, biological core of hormonal and antihormonal therapy of cancer and its prevention.
650 0 $aCancer$xEndocrine aspects.
650 12 $aBreast Neoplasms$xphysiopathology.
650 22 $aBreast Neoplasms$xdrug therapy.
650 22 $aEstrogen Receptor Modulators$xpharmacology.
650 22 $aReceptors, Estrogen$xphysiology.
650 22 $aReceptors, Progesterone$xphysiology.
700 1 $aBerstein, Lev M.
700 1 $aSanten, Richard J.
988 $a20080616
906 $0OCLC